

=> d bib abs hitstr 113

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 1999:451303 CAPLUS

DN 131:73842

TI Process for preparing carboxamido-4-azasteroids

IN Panzeri, Achille; D'Anello, Matteo; Longo, Antonio; Nesi, Marcella

PA Pharmacia & Upjohn Spa, Italy

SO PCT Int. Appl., 24 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9935161	A1	19990715	WO 1998-EP8527	19981217
	W:	AL, AU, BA, BG, BR, CA, CN, CZ, EE, HU, ID, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9925146	A1	19990726	AU 1999-25146	19981217
	EP 970105	A1	20000112	EP 1998-966861	19981217
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI			
	NO 9904199	A	19991029	NO 1999-4199	19990830
PRAI	GB 1997-27522		19971231		
	WO 1998-EP8527		19981217		
OS	CASREACT 131:73842; MARPAT 131:73842				
GI					



AB A process for producing azasteroids of formula I [R, R1 = H, (fluorine substituted) alkyl, (fluorine substituted) phenylalkyl, etc.; R2 = H, (fluorine substituted) alkyl; R3 = H, absent] comprises treating the corresponding 17.β-carbonylimidazole intermediates with anhyd. acids in the presence of an amine and, optionally, hydrogenating the resulting compd. Thus, 3-oxo-4-azaandrost-5-ene-17.β-carbonyl-1-imidazole was reacted with 1,1,1,3,3,3-hexafluoro-2-phenylprop-2-ylamine and methanesulfonic acid to give II.

IT 188754-88-3P


RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

Searched by John Dantzman

308-4488

(prepn. of 17.β.-carboxamido-4-azasteroids)
 RN 188754-88-3 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-
 tetradecahydro-4a,6a-dimethyl-2-oxo-N-[2,2,2-trifluoro-1-phenyl-1-
 (trifluoromethyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




IT 155651-56-2P 188754-67-8P 188754-68-9P
 188754-71-4P 198127-79-6P 229183-13-5P
 229183-14-6P 229183-15-7P 229183-16-8P
 229183-17-9P 229183-18-0P 229183-19-1P
 229183-20-4P 229183-21-5P 229183-22-6P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
 (Preparation)

(prepn. of 17.β.-carboxamido-4-azasteroids)

RN 155651-56-2 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-2-oxo-N-(2,2,2-trifluoro-1-methyl-1-
 phenylethyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 188754-67-8 CAPLUS

Searched by John Dantzman

308-4488


CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
11a-tetradecahydro-4a,6a-dimethyl-2-oxo-N-[2,2,2-trifluoro-1-phenyl-1-(trifluoromethyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 188754-68-9 CAPLUS
CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-4a,6a-dimethyl-2-oxo-N-[2,2,2-trifluoro-1-phenyl-1-(trifluoromethyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188754-71-4 CAPLUS
CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
11a-tetradecahydro-4a,6a-dimethyl-2-oxo-N-[2,2,2-trifluoro-1-(4-methylphenyl)-1-(trifluoromethyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198127-79-6 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-4a,6a-dimethyl-2-oxo-N-(2,2,2-trifluoro-1-methyl-1-phenylethyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229183-13-5 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, 2,4a,4b,5,6,6a,7,8,9,9a,9b,10-dodecahydro-4a,6a-dimethyl-2-oxo-N-[2,2,2-trifluoro-1-phenyl-1-(trifluoromethyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229183-14-6 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-4a,6a-dimethyl-2-oxo-N-[2,2,2-trifluoro-1-(4-methylphenyl)-1-(trifluoromethyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229183-15-7 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, 2,4a,4b,5,6,6a,7,8,9,9a,9b,10-dodecahydro-4a,6a-dimethyl-2-oxo-N-[2,2,2-trifluoro-1-(4-methylphenyl)-1-(trifluoromethyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 229183-16-8 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-

tetradecahydro-4a,6a-dimethyl-2-oxo-N-[2,2,2-trifluoro-1-(4-methylphenyl)-
1-(trifluoromethyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS)- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 229183-17-9 CAPLUS


CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, 2,4a,4b,5,6,6a,7,8,9,9a,9b,10-
dodecahydro-4a,6a-dimethyl-2-oxo-N-(2,2,2-trifluoro-1-methyl-1-
phenylethyl)-, (4aR,4bS,6aS,7S,9aS,9bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 229183-18-0 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-
 tetradecahydro-4a,6a-dimethyl-2-oxo-N-(2,2,2-trifluoro-1-methyl-1-
 phenylethyl)-, (4aR,4bS,6aS,7S,9aS,9bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229183-19-1 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-2-oxo-N-[2,2,2-trifluoro-1-methyl-1-(4-
 methylphenyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 229183-20-4 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-4a,6a-dimethyl-2-oxo-N-[2,2,2-trifluoro-1-methyl-1-(4-methylphenyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229183-21-5 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, 2,4a,4b,5,6,6a,7,8,9,9a,9b,10-dodecahydro-4a,6a-dimethyl-2-oxo-N-[2,2,2-trifluoro-1-methyl-1-(4-methylphenyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 229183-22-6 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,

2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-

tetradecahydro-4a,6a-dimethyl-2-oxo-N-[2,2,2-trifluoro-1-methyl-1-(4-methylphenyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 129273-17-2P 229183-12-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 17.beta.-carboxamido-4-azasteroids)

RN 129273-17-2 CAPLUS

CN 1H-Imidazole, 1-[[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-

2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 229183-12-4 CAPLUS

CN 1H-Imidazole,

1-[[(4aR, 4bS, 6aS, 7S, 9aS, 9bS)-2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,
10-tetradecahydro-4a,6a-dimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-
yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr l13 2

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 1994:457781 CAPLUS

DN 121:57781

TI Fluorinated 17.beta.-substituted 4-aza-5.alpha.-androstan-3-one
 derivatives useful as testosterone 5.alpha.-reductase inhibitors, and
 their preparation

IN Panzeri, Achille; Nesi, Marcella; Di Salle, Enrico

PA Farmitalia Carlo Erba S.R.L., Italy

SO PCT Int. Appl., 70 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9403475	A1	19940217	WO 1993-EP2037	19930729
	W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CN 1085224	A	19940413	CN 1993-109305	19930729
	CN 1041096	B	19981209		
	ZA 9305481	A	19940516	ZA 1993-5481	19930729
	EP 607400	A1	19940727	EP 1993-917705	19930729
	EP 607400	B1	19971105		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
	HU 67043	A2	19950130	HU 1994-914	19930729
	AU 660562	B2	19950629	AU 1993-47048	19930729
	AT 159951	E	19971115	AT 1993-917705	19930729
	IL 106520	A1	19971120	IL 1993-106520	19930729
	ES 2110620	T3	19980216	ES 1993-917705	19930729
	NO 9401080	A	19940518	NO 1994-1080	19940324
	FI 9401424	A	19940527	FI 1994-1424	19940328
PRAI	GB 1992-16284		19920731		
	WO 1993-EP2037		19930729		
OS	MARPAT 121:57781				
GI					



I



II

AB Title steroids I [B = bond, straight or branched C1-C6 alkylene; R = H, C1-C6 (fluoro)alkyl; R1 = H, C1-C6 (fluoro)alkyl, benzyl; R2 = (a) H, F, C1-C6 (fluoro)alkyl, C5-C7 cycloalkyl, C6-C9 cycloalkylalkyl; or (b) (un)substituted aryl or C7-C10 arylalkyl; R3 = (a) H, F, C1-C4 (fluoro)alkyl; or (b) (un)substituted aryl or C7-C10 arylalkyl; R4 = H, F,

or is absent when A is bound by double bond; R5 = H, F, C1-C6 (fluoro)alkyl; A = H, F, CR6R7R8, :CR6R7; R6, R7, R8 = H, F, C1-C6 (fluoro)alkyl; with the proviso that .gtoreq. 1 of groups R-R5 or A contains .gtoreq. 1 F atom], including 44 specifically named compds., are claimed, and several example preps. are given. For example, S-(2-pyridyl) 3-oxo-4-aza-5.alpha.-andros-1-ene-17.beta.-carbothioate was treated with MeI in CH2Cl2 and then with (.+-.)-PhC(Me)(CF3)NH2 in DMF, and the mixt. was heated at 100.degree. for 8 h to give title compd. II. At 3 mg/kg/day orally, II gave 54% inhibition of testosterone-induced prostatic hypertrophy in castrated rats. Three std. pharmaceutical formulations are described.

IT 155651-61-9

RL: RCT (Reactant)

(Wittig reaction of, in prepn. of antiandrogens)


RN 155651-61-9 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,

2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,

11a-tetradecahydro-4a,6a-dimethyl-2-oxo-N-(3,3,3-trifluoro-1-methyl-2-oxopropyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 155651-27-7


RL: RCT (Reactant)

(hydrogenation of, in prepn. of antiandrogens)

RN 155651-27-7 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 hexadecahydro-4a,6a-dimethyl-N-[1-
 methyl-2-(trifluoromethyl)-2-propenyl]-3-oxo-,
 (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 155651-63-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and redn. of, in prepn. of antiandrogens)

RN 155651-63-1 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,

11a-tetradecahydro-4a,6a-dimethyl-2-oxo-N-[3,3,3-trifluoro-2-(1H-imidazol-
 1-ylthioxomethoxy)-1-methylpropyl]-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




IT 155651-17-5P 155651-18-6P 155651-19-7P
 155651-20-0P 155651-21-1P 155651-22-2P
 155651-23-3P 155651-24-4P 155651-25-5P
 155651-26-6P 155651-27-7P 155651-28-8P
 155651-29-9P 155651-30-2P 155651-31-3P
 155651-32-4P 155651-33-5P 155651-34-6P
 155651-35-7P 155651-36-8P 155651-37-9P
 155651-38-0P 155651-39-1P 155651-40-4P
 155651-41-5P 155651-42-6P 155651-43-7P
 155651-44-8P 155651-45-9P 155651-46-0P
 155651-47-1P 155651-48-2P 155651-49-3P
 155651-50-6P 155651-51-7P 155651-52-8P
 155651-53-9P 155651-54-0P 155651-55-1P
 155651-56-2P 155651-57-3P 155651-58-4P
 155651-59-5P 155850-26-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of, as testosterone 5.alpha.-reductase inhibitor)

RN 155651-17-5 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 hexadecahydro-1,4a,6a-trimethyl-3-
 oxo-N-(3,3,3-trifluoro-1,2-dimethylpropyl)-,
 (4aR,4bS,6aS,7S,9aS,9bS,11aR)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155651-18-6 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,


hexadecahydro-1,4a,6a-trimethyl-N-

[2-methyl-1-(trifluoromethyl)propyl]-3-oxo-,

(4aR,4bS,6aS,7S,9aS,9bS,11aR)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155651-19-7 CAPLUS


CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-4a,6a-dimethyl-3-

oxo-N-(3,3,3-trifluoro-1,2-dimethylpropyl)-,

(4aR,4bS,6aS,7S,9aS,9bS,11aR)-


(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-20-0 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 hexadecahydro-4a,6a-dimethyl-N-[2-
 methyl-1-(trifluoromethyl)propyl]-3-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155651-21-1 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 N-[1-(2,2-difluoro-1-methylethyl)-
 3-methylbutyl]hexadecahydro-1,4a,6a-trimethyl-3-oxo-,
 (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 155651-22-2 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2-(difluoromethyl)-1-methylhexyl]hexadecahydro-1,4a,6a-trimethyl-3-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 155651-23-3 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[1-(2,2-difluoro-1-methylethyl)-3-methylbutyl]hexadecahydro-4a,6a-dimethyl-3-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 155651-24-4 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2-(difluoromethyl)-1-methylhexyl]hexadecahydro-4a,6a-dimethyl-3-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 155651-25-5 CAPLUS


CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-1,4a,6a-trimethyl-N-[1-methyl-2-(trifluoromethyl)-2-propenyl]-3-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-26-6 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 hexadecahydro-1,4a,6a-trimethyl-N-
 [2-methyl-1-(trifluoromethyl)-2-propenyl]-3-oxo-,
 (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-27-7 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 hexadecahydro-4a,6a-dimethyl-N-[1-
 methyl-2-(trifluoromethyl)-2-propenyl]-3-oxo-,
 (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-28-8 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 hexadecahydro-4a,6a-dimethyl-N-[2-
 methyl-1-(trifluoromethyl)-2-propenyl]-3-oxo-,
 (4aR,4bS,6aS,7S,9aS,9bS,11aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155651-29-9 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[1-(2,2-difluoro-1-
 methylethenyl)-3-methylbutyl]hexadecahydro-1,4a,6a-trimethyl-3-oxo-,
 (4aR,4bS,6aS,7S,9aS,9bS,11aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 155651-30-2 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2-(difluoromethylene)-1-methylhexyl]hexadecahydro-1,4a,6a-trimethyl-3-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 155651-31-3 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[1-(2,2-difluoro-1-methylethenyl)-3-methylbutyl]hexadecahydro-4a,6a-dimethyl-3-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 155651-32-4 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2-(difluoromethylene)-1-methylhexyl]hexadecahydro-4a,6a-dimethyl-3-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 155651-33-5 CAPLUS


CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-3-oxo-N-(2,2,2-trifluoroethyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-34-6 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-3-oxo-N,N-bis(2,2,2-trifluoroethyl)-,
 (4aR,4bS,6aS,7S,9aS,9bS,11aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-35-7 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-3-oxo-N-[2,2,2-trifluoro-1-
 (trifluoromethyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS,11aR) - (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 155651-36-8 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-3-oxo-N,N-bis[2,2,2-trifluoro-1-
 (trifluoromethyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 155651-37-9 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-N,4a,6a-trimethyl-3-oxo-N-(2,2,2-trifluoroethyl)-,
 (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-38-0 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-N-(2-methylpropyl)-3-oxo-N-(2,2,2-
 trifluoroethyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155651-39-1 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-(2-fluoro-1,1-dimethylethyl)-
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-3-oxo-,
 (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 155651-40-4 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2-fluoro-1-(fluoromethyl)-1-methylethyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-3-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-41-5 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2-fluoro-1,1-bis(fluoromethyl)ethyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-3-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 155651-42-6 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-4a,6a-dimethyl-3-oxo-N-[3,3,3-trifluoro-2-methyl-1-(1-methylethyl)propyl]-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 155651-43-7 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-4a,6a-dimethyl-3-oxo-N-(3,3,3-trifluoro-1,1,2-trimethylpropyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155651-44-8 CAPLUS


CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,

2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,

11a-tetradecahydro-4a,6a-dimethyl-3-oxo-N-(3,3,3-trifluoro-1,2-

dimethylpropyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-45-9 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,

2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,

11a-tetradecahydro-4a,6a-dimethyl-3-oxo-N-[3,3,3-trifluoro-2-methyl-1-(1-methylethyl)propyl]-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-46-0 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,

2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,

11a-tetradecahydro-4a,6a-dimethyl-3-oxo-N-(3,3,3-trifluoro-1,1,2-trimethylpropyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-47-1 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,

2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,


11a-tetradecahydro-4a,6a-dimethyl-3-oxo-N-(3,3,3-trifluoro-1-methylpropyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-48-2 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-3-oxo-N-(3,3,3-trifluoro-1,1-
 dimethylpropyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155651-49-3 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-N-[1-methyl-2-(trifluoromethyl)-2-
 propenyl]-3-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-50-6 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,

11a-tetradecahydro-4a,6a-dimethyl-N-[1-(1-methylethyl)-2-(trifluoromethyl)-
2-propenyl]-3-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-51-7 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[1,1-dimethyl-2-
(trifluoromethyl)-2-propenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-
tetradecahydro-4a,6a-dimethyl-3-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR) -
(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 155651-52-8 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
hexadecahydro-1,4a,6a-trimethyl-3-

oxo-N-(2,2,2-trifluoroethyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 155651-53-9 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,

11a-tetradecahydro-4a,6a-dimethyl-N-(1-methylethyl)-3-oxo-N-(2,2,2-
trifluoroethyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-54-0 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,

2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,

11a-tetradecahydro-4a,6a-dimethyl-N-(1-methylethyl)-3-oxo-N-(2,2,3,3,3-pentafluoropropyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-55-1 CAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,

2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,


11a-tetradecahydro-4a,6a-dimethyl-3-oxo-N-(2,2,2-trifluoro-1-phenylethyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-56-2 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-2-oxo-N-(2,2,2-trifluoro-1-methyl-1-
 phenylethyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-57-3 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-3-oxo-N-(2,2,2-trifluoro-1,1-
 diphenylethyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-58-4 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-3-oxo-N-(2,2,2-trifluoro-1,1-
 dimethylethyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 155651-59-5 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-3-oxo-N-[2,2,2-trifluoro-1-methyl-1-
 (trifluoromethyl)ethyl]-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 155850-26-3 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-2-oxo-N-[3,3,3-trifluoro-1-(1-
 methylethyl)propyl]-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



IT 155651-62-0
 RL: RCT (Reactant)
 (thioesterification and redn. of, in prepn. of antiandrogens)
 RN 155651-62-0 CAPLUS
 CN 1H-Indeno[5,4-f]quinoline-7-carboxamide,
 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,
 11a-tetradecahydro-4a,6a-dimethyl-2-oxo-N-(3,3,3-trifluoro-2-hydroxy-1-
 methylpropyl)-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

